welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas
Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Progression-free survival is the length of time patients lived before their disease worsened. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.
The trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH); designed and conducted by researchers with the Alliance for Clinical Trials in Oncology (Alliance); and supported by Bayer HealthCare AG, which provided the study drug.
expertly curated content related to this topic
-
Feza H. Remzi, MDDr. Feza Remzi is a gastroenterologist i...
-
Banner MD Anderson Cancer CenterAt Banner MD Anderson Cancer Center, col...
-
Matthew Kalady, MDMatthew Kalady, MD, holds the Krause-Lie...
-
Steven H. Itzkowitz, MDDr. Itzkowitz is past Chair of the Gastr...
-
Uri Ladabaum, MDUri Ladabaum, MD is a Professor of Medic...
-
Non-Invasive Prediction of Colorectal NeoplasiaHypothesis:The Adnab-9 antigen is a ...
-
Desmoid Tumour in Familial Adenomatous Polyposis Patients: Responses to TreatmentsNo guidelines for desmoid tumors (DT) ma...